shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)

    RFA-NS-22-034

    National Institutes of Health

    Opening date 7 Jan 2022, 12:00AM

    Closing date 6 Dec 2024, 12:00AM

    Funding Opportunity Number: RFA-NS-22-034

    Opportunity Category: Discretionary

    CFDA Number(s): 93.121 -- Oral Diseases and Disorders Research,93.213 -- Research and Training in Complementary and Integrative Health,93.273 -- Alcohol Research Programs,93.350 -- National Center for Advancing Translational Sciences,93.393 -- Cancer Cause and Prevention Research,93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research,93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research,93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders,93.865 -- Child Health and Human Development Extramural Research,93.866 -- Aging Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Jan 07, 2022 12:00:00 AM EST

    Closing Date: Dec 06, 2024 12:00:00 AM EST

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: Others (see text field entitled "Additional Information on Eligibility" for clarification),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Public housing authorities/Indian housing authorities,Small businesses,Public and State controlled institutions of higher education,City or township governments,Native American tribal governments (Federally recognized),Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Special district governments,For profit organizations other than small businesses,State governments,County governments,Native American tribal organizations (other than Federally recognized tribal governments),Private institutions of higher education,Independent school districts

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Agency Name: National Institutes of Health

    Description: The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices are not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.

    Grantor Contact Information: NIH OER Webmaster OERWebmaster03@od.nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept